Embracing Innovation and Security: Medtech Growth in 2024

March 14, 2024
Article Imagry

The medical technology (Medtech) sector is on the cusp of significant growth in 2024, with a strategic pivot towards profitable ventures and the adoption of artificial intelligence (AI). This sets the stage for a competitive edge for early adopters. Evolving healthcare trends highlight the need for software security investment. They also show how crucial staff acceptance is for new technology success.

The Surge in Medtech Innovation

A recent analysis by McKinsey & Company paints an optimistic future for the Medtech industry, stressing the importance of innovation—especially in AI—as a means to secure a competitive edge. The FDA’s approval of an unprecedented number of novel medical technologies in 2023. Advancements in AI, machine learning, miniaturization, and sectors such as neuromodulation and robotics particularly drove this, setting the pace. With faster approval times and a push towards innovation, we anticipate 2024 will continue to see growth in areas like cardiovascular technology, digital health devices, and neuromodulation. Furthermore, this wave of innovation, propelled by enhanced imaging techniques and new treatment options, not only promises growth but also poses a challenge for Medtech firms to prioritize groundbreaking innovations over incremental improvements. 

FDA Approvals

The Critical Need for Security

The expansion of telemedicine and remote monitoring services has elevated security as a crucial concern. Insights from Gartner recommend that executives invest heavily in security measures to strengthen their digital infrastructure, safeguarding patient data and maintaining trust.

Security cover

Innovation as a Strategy for Profitable Growth

The pursuit of innovation transcends technological advancement, aiming to ensure that such progress translates into profitable growth. McKinsey’s findings reveal a significant increase in the correlation between profit margin improvement and valuation since 2019. Medtech leaders have enhanced their profitability in recent years. Consequently, they are expected to further boost their EBITA margins by at least 200 basis points in the forthcoming years. This highlights the profitable potential of strategic innovation.

Navigating the Future Landscape

As we move closer to 2024, pharmaceutical executives face a myriad of challenges and opportunities in both innovation and security. By strategically tackling these areas, pharma companies are not just poised for sustained growth. Additionally, they are set to significantly contribute to the advancement of global healthcare. This marks a new era in Medtech where innovation and security are the keystones of success.

About Comrise

At Comrise, we offer tailored solutions for the full-time, part-time, direct-hire, contract, and permanent talent that your business needs. For 40+ years, we have delighted our clients and candidates by focusing on customer satisfaction, innovation, and flexible workforce solutions! 

If you’re looking for new job opportunities click here, or if you’re looking for a reliable partner to help you secure top-notch candidates for hard-to-fill roles, click here.

Related Posts

ESG Regional Market Regulation Differences

July 16, 2024

Environmental, social, and governance (ESG) standards have gained importance with the increasing global emphasis on sustainable development and corporate social responsibility. These standards evaluate the performance and contributions of enterprises...

The Rise of Robotaxi: Revolutionizing Urban Mobility in China

July 16, 2024

Recently, Baidu rolled out 1,000 “Apollo Go” unmanned cars in Wuhan, triggering a social debate. This means that the concept of true self-driving mobility is getting closer. Robotaxi opens the...

Comrise Announces the Relocation of Southeast Asia Office

July 2, 2024

Manila, Philippines – June 28, 2024 – Comrise, a leading global HR service provider based in the U.S., proudly announces the relocation of its Southeast Asia office. The opening ceremony,...

Global Contact Information

We have offices across the globe. Please ensure that you are getting in touch with the correct office for your region.

United States

Woodbridge, NJ (Global HQ)

90 Woodbridge Center Drive Suite 360
Woodbridge, NJ 07095

Tel: 1-732-739-2330
Fax: 1-732-739-1996

Philippines

Metro Manila

1105 Raffles Corporate Center, Ortigas Center, Pasig City, Metro Manila, Philippines

Malaysia

Kuala Lumpur

Unit B12, Level 1, Menara BT, Tower 3, Avenue 7,
Horizon Phase 2, Bangsar South, No.8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia

Tel: +60-03-27794130

 

Beijing

Room 1015, 10/F, Hanweidasha Building, Guanghualu Road, Chaoyang District, Beijing,100020

Tel: +86 10 58780578

北京市朝阳区光华路7号汉威大厦东区1015室

邮编:100020
电话:+86 10 58780578

Qingdao

Room 822, 8F, Building 1, HNA Center, 234 Yan’an Third Road, Shinan District, Qingdao, China

Tel: +86 532 68669385

山东省青岛市海尔路182-8号半岛国际大厦2104室

邮编:266000
电话:+86 532 68669385

Shanghai

Room 18F/G/H, Shanghai Industrial Investment Building, No.18 Caoxi Road, Xuhui District, Shanghai, 200030

Tel: +86 21 64270570

上海市徐汇区漕溪北路18号上海实业大厦18楼F/G/H座

邮编:200030
电话:+86 21 64270570

Chengdu

26th Floor Bldg.2,No.88 Jitai 5th Road, Xiangnian Square, Tianfu Avenue, Hi-Tech Zone, Chengdu, Sichuan, 610041

Tel: +86 28 86703369

四川省成都市高新区天府大道中段吉泰五路88号香年广场T2座26层

邮编:610041
电话:+86 28 86703369

Wan Chai, Hong Kong

EA Licence no. 66051 & 64845

5/F Heng Shan Centre, 145 Queen’s Road East, Wan Chai, Hong Kong

Tel: +852 36223225

牌照号码: 66051 & 64845

香港湾仔皇后大道东145号恒山中心5楼

电话:+852 36223225

Wuhan

Room 1419, 14 / F, Building A, New World Center, No. 634, Jiefang Street, Qiaokou District, Wuhan, Hubei

Xi’an

C17, 18 / F, Block E, Chang’an International Center, 88 Nanguanzheng street, Xi’an, Shaanxi

Hefei

A11-10, 1701, Building 7, Wanda Office Building, Wuhu Road, Hefei, Anhui

Change Language